Pfizer, Inc. · NYSE:PFE
Pfizer — Morgan Stanley R&D Insight Panel Day 2016
6 slides from Pfizer's conference presentation, Apr 12, 2016
Slide 1: Accelerating Impactful Medicines to Market
Accelerating Impactful Medicines to Market Morgan Stanley R&D Insight Panel Day Mikael Dolsten, M.D., Ph.D. President Pfizer Worldwide R&D April 12, 2016
Slide 2: Forward-looking Statements
Forward-looking Statements • This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are s
Slide 3: Strong Track Record of Approvals
Strong Track Record of Approvals Over the last 6 years >25 Phase 3 starts & >15 key approvals (10 NME’s) (Adult / CAPITA) Robust Pipeline Positioned for Sustainable Productivity ~50% biologics, biosimilars and vaccines 214 Discovery Discovery Phase 1 Phase 2 Phase 3 Registration 90 Projects Projects
Slide 4: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products Potential for more than 20 approvals, including up to 10 NMEs by ~2020 ONCOLOGY RARE DISEASE Ibrance: Breast Cancer & Beyond rivipansel, PDE9 SCD IO: PD-L1, 4-1BB, OX40, CART, Combo FIX Gene Therapy, TFPI Hemophilia Targeted: inotuzumab, lo
Slide 5: Potential 2016 News Flow
Potential 2016 News Flow LATE STAGE Xeljanz ertugliflozin PsA Ph 3 Data Ph 3 Data bococizumab LDL Xalkori Ph 3 Data ROS1 NSCLC Approval 1H 2016 2H 2016 EARLY STAGE p-cadherin avelumab Bi-Fx FIH Ovarian,SCCHN POC Dopamine Mod. JAK1 PD Ph 2 Start AD Ph 2 Start For presentation; not for distribution 5
Slide 6: Potential 2016 News Flow
Potential 2016 News Flow LATE STAGE Xeljanz ertugliflozin avelumab inotuzumab PsA Ph 3 Data Ph 3 Data MCC Submission ALL Approval (US) bococizumab LDL Xalkori Xeljanz Ibrance Ph 3 Data ROS1 NSCLC Approval UC Ph 3 Data BC Approval (EU) 1H 2016 2H 2016 CART, IDO1 EARLY STAGE p-cadherin avelumab IO FIH